Chicago – the 2019 ASCO annual meeting is in full swing and it’s plenary Sunday where the jewels in the crown are presented.
Noteworthy this year is the olaparib data being presented by Dr Hedy Kindler.
In this post, we’ve commentary on the data we’ve heard so far, highlights from yesterday’s sessions, and what you can expect to hear today if you’re in Chicago for Plenary Sunday.
To learn more from our latest conference coverage and oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
As cancer becomes increasing complex with adaptive responses to therapeutic intervention, so our knowledge and strategies for overcoming it must also adapt and improve. Immunotherapy – in several forms – is probably the hottest topic on the landscape at the moment with both checkpoint inhibitors and chimeric antigen receptor technology (CART) vying for air time and attention but where are these approaches going and how can we harness the immune system more effectively?
One of the things I like most about AACR meetings is that there are nearly always some strategic gems emerging from the scientist-physician thought leaders if only you stop to think about how the field can rapidly change by looking at the early patterns that are emerging.
Here’s the first part of a synopsis of what I learned at the recent Molecular Targets meeting in Boston, some of these findings may well have a major impact on cancer research over the next few years…
Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content.